Literature DB >> 26185313

Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.

Hee Jin Lee1, Joo Young Kim2, In Ah Park1, In Hye Song1, Jong Han Yu3, Jin-Hee Ahn4, Gyungyub Gong5.   

Abstract

OBJECTIVES: Tumor-infiltrating lymphocytes (TILs) have prognostic significance in breast cancer. The tertiary lymphoid structure (TLS) is related to the influx of TILs, and expression of major histocompatibility complex (MHC) I in tumor cells is necessary for the effective action of TILs.
METHODS: We retrospectively evaluated the relationship of TILs and TLS and the expression of MHC I in 447 HER2-positive breast cancers treated with chemotherapy and 1 year of trastuzumab.
RESULTS: TILs were more abundant in hormone receptor (HR)-/HER2+ tumors than in HR+/HER2+ tumors. HR-/HER2+ breast cancers with abundant TILs showed a higher histologic grade, the absence of lymphovascular invasion, the presence of peritumoral lymphocytic infiltration, moderate to abundant TLSs in adjacent tissue, and stronger HLA-ABC and HLA-A expression. Abundant TILs and the absence of lymphovascular invasion were found to be good, independent prognostic factors for disease-free survival in patients with HR-/HER2+ breast cancer. The level of TILs was not associated with the patients' prognosis in HR+ tumors.
CONCLUSIONS: Abundant TILs are an independent prognostic factor in HR-/HER2+ breast cancers. Evaluation of TILs in HR-/HER2+ breast cancers may provide valuable information regarding the prognosis of patients treated using adjuvant chemotherapy and trastuzumab. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Breast carcinoma; HER2; Lymphocytes; MHC I; Tertiary lymphoid structure; Trastuzumab

Mesh：

Substances：

Year:  2015        PMID： 26185313     DOI： 10.1309/AJCPIXUYDVZ0RZ3G

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  42 in total

1.  Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.

Authors:  Xia Liu; Julia Y S Tsang; Thazin Hlaing; Jintao Hu; Yun-Bi Ni; Siu Ki Chan; Sai Yin Cheung; Gary M Tse
Journal:  Oncologist       Date:  2017-07-12

Review 2.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

3.  Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Authors:  Laurence Buisseret; Christine Desmedt; Soizic Garaud; Marco Fornili; Xiaoxiao Wang; Gert Van den Eyden; Alexandre de Wind; Sebastien Duquenne; Anais Boisson; Celine Naveaux; Francoise Rothé; Sandrine Rorive; Christine Decaestecker; Denis Larsimont; Martine Piccart-Gebhart; Elia Biganzoli; Christos Sotiriou; Karen Willard-Gallo
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

Review 4.  Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

Authors:  Anthony B Rodriguez; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2020-11       Impact factor: 11.151

5.  Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

Authors:  Marcelo Sobral-Leite; Koen Van de Vijver; Magali Michaut; Rianne van der Linden; Gerrit K J Hooijer; Hugo M Horlings; Tesa M Severson; Anna Marie Mulligan; Nayana Weerasooriya; Joyce Sanders; Annuska M Glas; Diederik Wehkamp; Lorenza Mittempergher; Kelly Kersten; Ashley Cimino-Mathews; Dennis Peters; Erik Hooijberg; Annegien Broeks; Marc J van de Vijver; Rene Bernards; Irene L Andrulis; Marleen Kok; Karin E de Visser; Marjanka K Schmidt
Journal:  Oncoimmunology       Date:  2018-09-11       Impact factor: 8.110

6.  Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade.

Authors:  Chiara Secondini; Oriana Coquoz; Lorenzo Spagnuolo; Thibaud Spinetti; Sanam Peyvandi; Laura Ciarloni; Francesca Botta; Carole Bourquin; Curzio Rüegg
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

7.  CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer.

Authors:  Heejae Lee; Hee Jin Lee; In Hye Song; Won Seon Bang; Sun-Hee Heo; Gyungyub Gong; In Ah Park
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

8.  High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers.

Authors:  Hee Jin Lee; Joo Young Kim; In Hye Song; In Ah Park; Jong Han Yu; Jin-Hee Ahn; Gyungyub Gong
Journal:  Virchows Arch       Date:  2015-10-07       Impact factor: 4.064

Review 9.  Tertiary lymphoid structures in the era of cancer immunotherapy.

Authors:  Catherine Sautès-Fridman; Florent Petitprez; Julien Calderaro; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

10.  Transcriptomic and Immunophenotypic Characterization of Tumor Immune Microenvironment in Squamous Cell Carcinoma of the Oral Tongue.

Authors:  Kyriakos Chatzopoulos; Sotiris Sotiriou; Andrea R Collins; Panagiotis Kartsidis; Alessandra C Schmitt; Xianfeng Chen; Khashayarsha Khazaie; Michael L Hinni; Colleen A Ramsower; Matthew A Zarka; Samir H Patel; Joaquin J Garcia
Journal:  Head Neck Pathol       Date:  2020-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.